Geographic variation in delay to surgical treatment among non-small cell lung cancer patients.

IF 4.5 2区 医学 Q1 ONCOLOGY
Getayeneh Antehunegn Tesema, Rob G Stirling, Win Wah, Zemenu Tadesse Tessema, Stephane Heritier, Arul Earnest
{"title":"Geographic variation in delay to surgical treatment among non-small cell lung cancer patients.","authors":"Getayeneh Antehunegn Tesema, Rob G Stirling, Win Wah, Zemenu Tadesse Tessema, Stephane Heritier, Arul Earnest","doi":"10.1016/j.lungcan.2024.108077","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Delayed surgery is significantly associated with an increased risk of disease progression and adverse outcomes in lung cancer. Evidence is available on the variation in delayed surgical treatment among patients with Non-Small Cell Lung Cancer (NSCLC). However, the relative contribution of patient- and area-level risk factors to the geographic patterns of delayed surgery in patients with NSCLC is poorly understood. Therefore, we aimed to explore the geographic variation in delay to surgical treatment among patients with NSCLC.</p><p><strong>Materials and methods: </strong>This study utilized data from the Victorian Lung Cancer Registry (VLCR) and the Australian Bureau of Statistics (ABS). A total of 3,088 patients with NSCLC who had undergone surgery were included. We applied a Bayesian spatial multilevel model incorporating spatially structured and unstructured random effects to examine patient and area-level risk factors associated with delays to surgical treatment. Model comparison was conducted using the Deviance Information Criterion (DIC).</p><p><strong>Results: </strong>Over one-third (40.45 %) of NSCLC patients experienced delayed surgical treatment. Significant geographic variation in delayed surgical treatment among NSCLC patients across Local Government Areas (LGAs) was observed. Factors significantly associated with higher odds of delayed surgical treatment included clinical stage II (AOR = 1.56, 95 % CrI: 1.26-1.92), stage III (AOR = 1.90, 95 % CrI: 1.46-2.47), stage IV (AOR = 2.04, 95 % CrI: 1.15-3.61), treatment at inner regional hospitals (AOR = 2.86, 95 % CrI: 2.17-3.70), presence of comorbidities (AOR = 1.19, 95 % CrI: 1.02-1.40), and diagnosis during the COVID-19 pandemic (AOR = 1.32, 95 % CrI: 1.10-1.57).</p><p><strong>Conclusions: </strong>This study highlights the need to improve the treatment pathway for patients with NSCLC by reducing the time between diagnosis and surgery. Future targeted initiatives are essential to promote timely surgeries for NSCLC patients, especially in high-need areas.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"199 ","pages":"108077"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.lungcan.2024.108077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Delayed surgery is significantly associated with an increased risk of disease progression and adverse outcomes in lung cancer. Evidence is available on the variation in delayed surgical treatment among patients with Non-Small Cell Lung Cancer (NSCLC). However, the relative contribution of patient- and area-level risk factors to the geographic patterns of delayed surgery in patients with NSCLC is poorly understood. Therefore, we aimed to explore the geographic variation in delay to surgical treatment among patients with NSCLC.

Materials and methods: This study utilized data from the Victorian Lung Cancer Registry (VLCR) and the Australian Bureau of Statistics (ABS). A total of 3,088 patients with NSCLC who had undergone surgery were included. We applied a Bayesian spatial multilevel model incorporating spatially structured and unstructured random effects to examine patient and area-level risk factors associated with delays to surgical treatment. Model comparison was conducted using the Deviance Information Criterion (DIC).

Results: Over one-third (40.45 %) of NSCLC patients experienced delayed surgical treatment. Significant geographic variation in delayed surgical treatment among NSCLC patients across Local Government Areas (LGAs) was observed. Factors significantly associated with higher odds of delayed surgical treatment included clinical stage II (AOR = 1.56, 95 % CrI: 1.26-1.92), stage III (AOR = 1.90, 95 % CrI: 1.46-2.47), stage IV (AOR = 2.04, 95 % CrI: 1.15-3.61), treatment at inner regional hospitals (AOR = 2.86, 95 % CrI: 2.17-3.70), presence of comorbidities (AOR = 1.19, 95 % CrI: 1.02-1.40), and diagnosis during the COVID-19 pandemic (AOR = 1.32, 95 % CrI: 1.10-1.57).

Conclusions: This study highlights the need to improve the treatment pathway for patients with NSCLC by reducing the time between diagnosis and surgery. Future targeted initiatives are essential to promote timely surgeries for NSCLC patients, especially in high-need areas.

非小细胞肺癌患者延迟手术治疗的地理差异。
目的:延迟手术与肺癌疾病进展风险增加和不良结局显著相关。有证据表明非小细胞肺癌(NSCLC)患者延迟手术治疗的差异。然而,患者和区域水平的危险因素对NSCLC患者延迟手术的地理模式的相对贡献尚不清楚。因此,我们旨在探讨非小细胞肺癌患者延迟手术治疗的地理差异。材料和方法:本研究使用了维多利亚州肺癌登记处(VLCR)和澳大利亚统计局(ABS)的数据。共纳入了3,088例接受过手术的非小细胞肺癌患者。我们应用贝叶斯空间多层模型结合空间结构化和非结构化随机效应来检查与延迟手术治疗相关的患者和区域层面的风险因素。采用偏差信息准则(DIC)进行模型比较。结果:超过三分之一(40.45%)的非小细胞肺癌患者经历了延迟手术治疗。观察到不同地方政府区域(LGAs)的非小细胞肺癌患者延迟手术治疗的显著地理差异。与延迟手术治疗几率较高相关的因素包括临床II期(AOR = 1.56, 95% CrI: 1.26-1.92)、III期(AOR = 1.90, 95% CrI: 1.46-2.47)、IV期(AOR = 2.04, 95% CrI: 1.15-3.61)、在区域内医院治疗(AOR = 2.86, 95% CrI: 2.17-3.70)、是否存在合共病(AOR = 1.19, 95% CrI: 1.02-1.40)以及在COVID-19大流行期间诊断(AOR = 1.32, 95% CrI: 1.10-1.57)。结论:本研究强调需要通过缩短诊断和手术之间的时间来改善非小细胞肺癌患者的治疗途径。未来有针对性的举措对于促进NSCLC患者及时手术至关重要,特别是在高需求地区。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信